Drug Profile
GW 215864
Alternative Names: GR 215864X; GW 215864XLatest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antiasthmatics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Rhinitis
Most Recent Events
- 31 Dec 2000 Discontinued-I for Rhinitis in United Kingdom (Intranasal)
- 07 Feb 2000 Discontinued-II for Asthma in United Kingdom (Inhalation)
- 07 Feb 2000 Phase-I clinical trials for Rhinitis in United Kingdom (Intranasal)